PharmaMar signs licensing agreement with Seattle Genetics

Rachel Cresswell 20 February 2018

PharmaMar licenses fully synthetic marine-derived payloads to Seattle Genetics for use in drug conjugates. 


PharmaMar has announced the signing of an exclusive licensing agreement with Seattle Genetics under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the development, manufacture and commercialisation of antibody-drug conjugates (ADCs) and/or other drug conjugates incorporating PharmaMar payloads.

According to the terms of the agreement, PharmaMar receives an upfront payment of 5,000,000 US dollars on signing. In addition, PharmaMar is eligible for potential approval and sales milestones as well as royalties, once a product receives regulatory approval and is commercialised.

PharmaMar has a Marine Payloads unit. These are new, structurally diverse molecules with novel mechanisms of action that provide a unique opportunity to develop next generation ADCs. These payloads are highly potent, with sub-nanomolar cytotoxic activity. ADCs are targeted cancer treatments designed to harness the specificity of antibodies to deliver cell-killing agents directly to cancer cells.

Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, stated, "We are glad to sign this license agreement with Seattle Genetics, a pioneer and leading company in the ADC market, because it allows us to work together in these cutting-edge cancer treatments."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.